QIBA PET Amyloid Biomarker Committee
27 March 2015 at 9:00 AM CT (GMT-6)
Call Summary

In attendance:

**Co-chairs:** Satoshi Minoshima, MD, PhD  Eric Perlman, MD  Anne Smith, PhD

**Participants:** Orest Boyko, MD, PhD  Santiago (Santi) Bullich, PhD  Norman Foster, MD  John Hoffman, MD  Gregory Klein, PhD  Nancy Obuchowski, PhD

Amy Perkins, PhD  Sandra Sanabria, PhD  Rathan Subramaniam, MD, PhD  Daniel Sullivan, MD  Jean-Luc Vanderheyden, PhD

**RSNA:** Joe Koudelik  Julie Lisiecki

General Discussion:

- Updates were provided by two task force leaders:
  - Dr. Subramaniam (Claims/ Test-Retest) and Dr. Klein (Site validation)
  - Dr. Subramaniam discussed progress on the Claims (test-retest / meta-analysis) literature analysis.
    - Remaining questions:
      - What is the primary goal for the test-retest study?
      - What is the best time interval for obtaining test-retest data?
      - Does the time interval between base-line and follow up scan make a difference?
      - Can aggregate data stand alone?
    - Feedback from the BC is encouraged
      - Dr. Subramaniam to provide a cover email to accompany his spreadsheet with a request to the QIBA PET Amyloid BC re: the test-retest study
      - Another task force was suggested to work on $^{18}$F analysis to feed the Profile

- Dr. Klein discussed Profile recommendations for Sections 3.6.4 (Phantom Imaging) and 3.6.6 (Quality Control: Interpretation):
  - Consideration being given to revising section 3.6.4
    - Two levels/uses of physical phantom imaging will be included for the Profile:
      1. Initial scanner assessment to include Hoffman phantom (also to be performed after major hardware or software upgrade)
      2. Maintenance follow-up phantom imaging not requiring Hoffman phantom

- Use of either the Hoffman DRO, or an FDG PET DRO, with recommendations for image reconstruction, was also discussed
  - The DRO would be needed in addition to the physical phantom

- Concerns discussed regarding the physical phantoms:
  - Currently, only 50% of sites have either a Jaszcak or NEMA phantom
  - It is estimated that only about 5% of sites have the Hoffman DRO
    - However, everyone has a uniformity phantom, which could be tested more frequently

**Action items:**
- Dr. Subramaniam to provide cover email text for RSNA Staff to distribute his spreadsheet to the Amyloid BC for the test-retest study feedback
- Dr. Klein to update the Profile based on feedback from the call

**Proposed Nuclear Medicine Calendar for April (Fridays, 9 am CT):**
- **April 3** – FDG-PET Biomarker Ctte
- **April 10** – PET Amyloid Biomarker Ctte
- **April 17** – (proposed) SPECT Biomarker Ctte
- **April 24** – PET Amyloid Biomarker Ctte